by mfantozzi | Nov 12, 2021 | 2021, Press Releases, Scientific
Philogen to hold a Webinar at 11 am EST / 4 pm GMT / 5 pm CET on Friday 12th November 2021, Click here to view Press Release 12-11-2021by mfantozzi | Nov 4, 2021 | 2021, Past Events, Scientific
Dario Neri, co-founder, CEO and CSO, is giving a presentation to address the question on how to achieve the therapeutic dose at the tumor site with cytokine-based targeted products. Roberto De Luca, Head of Antibody Therapeutics at Philogen, is also giving a...by mfantozzi | Oct 15, 2021 | 2021, Press Releases, Scientific
Philogen announces that Philochem’s European Patent 3083957 relating to important features of proprietary DNA-encoded chemical libraries (“ESAC 2+1” technology) was upheld after Oral Proceedings in front of the Opposition Division at the European Patent Office. Read...by mfantozzi | Sep 29, 2021 | 2021, Press Releases, Scientific
Philogen provides corporate updateby mfantozzi | Aug 27, 2021 | 2021, Press Releases, Scientific
We are pleased to announce that Philogen co-founder and CEO/CSO, Prof. Dario Neri is giving two lectures on September 1st, 2021: At the virtual International Symposium on Medicinal Chemistry (EFMC-ISMC 2021) Prof. Neri is giving a presentation at 15:35 (CEST) with the...by last | Aug 23, 2021 | 2021, Press Releases, Scientific
Philochem, a wholly owned subsidiary of Philogen S.p.A., InterX, Inc and Scripps Research announce a research collaboration to develop a best-in-class tumor targeting agent for metastatic prostate cancer. Read More